Daratumumab is a human IgGκ monoclonal antibody that targets CD38, which is highly expressed on myeloma cells and other hematopoietic cell types. 5,6 Daratumumab has direct and indirect antitumor ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...

Daratumumab (Darzalex) with bortezomib and dexamethasone is available on the NHS as a possible treatment for multiple myeloma in adults, if they have only had 1 treatment before and: this included ...

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...